

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
22 July 2021 (22.07.2021)



(10) International Publication Number
WO 2021/146397 A1

(51) International Patent Classification:

A61K 35/74 (2015.01) *C12N 15/52* (2006.01)
A61P 3/00 (2006.01) *C12N 15/70* (2006.01)
C12N 1/00 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2021/013401

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:

14 January 2021 (14.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(30) Priority Data:

62/960,950	14 January 2020 (14.01.2020)	US
62/993,301	23 March 2020 (23.03.2020)	US
63/028,902	22 May 2020 (22.05.2020)	US
63/065,752	14 August 2020 (14.08.2020)	US
63/089,758	09 October 2020 (09.10.2020)	US
63/091,620	14 October 2020 (14.10.2020)	US
63/111,376	09 November 2020 (09.11.2020)	US

(71) Applicant: SYNLOGIC OPERATING COMPANY,
INC. [US/US]; 301 Binney Street, Suite 402, Cambridge,
MA 02142 (US).

(72) Inventors: ISABELLA, Vincent, M.; 38 Holton Street,
Medford, MA 02155 (US). LUBKOWICZ, David; 12
Cross Street E, #3, Somerville, MA 02145 (US). JAMES,
Michael; 15 Otis Street, Melrose, MA 02176 (US).

(74) Agent: CLARKE, Marcie, B. et al.; McCarter & English,
LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: BACTERIA ENGINEERED TO TREAT DISORDERS IN WHICH OXALATE IS DETRIMENTAL

(57) Abstract: The present invention provides recombinant bacterial cells comprising at least one heterologous gene encoding at least one oxalate catabolism enzyme. In another aspect, the recombinant bacterial cells further comprise at least one heterologous gene encoding an importer of oxalate. The invention further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders in which oxalate is detrimental, such as hyperoxaluria, using the pharmaceutical compositions of the invention.

WO 2021/146397 A1